mRNA Products

Description: CleanCap M6 Cre mRNA (N1MePsU) is a specialized mRNA product encoding Cre recombinase fused to a nuclear localization sequence (NLS). This mRNA is capped using CleanCap Reagent M6, which produces a base-modified Cap-1 structure with superior in vivo activity compared to traditional Cap-0 mRNA. The mRNA is polyadenylated and fully substituted with N1-methylpseudouridine (N1MePsU), which reduces immunogenicity and enhances translational efficiency, resulting in increased protein expression. This product is ideal for applications such as CRISPR-based genome editing and gene expression studies.

CAT: BRP-02561

Concentration: 1.0 mg/mL

Description: CleanCap M6 Cas9 mRNA (N1MePsU) is a specialized mRNA product encoding the CRISPR-associated protein Cas9, which is a key component of the CRISPR genome editing system. This mRNA is capped using CleanCap Reagent M6, which produces a base-modified Cap-1 structure with superior in vivo activity compared to traditional Cap-0 mRNA. The mRNA is polyadenylated and fully substituted with N1-methylpseudouridine (N1MePsU), which reduces immunogenicity and enhances translational efficiency, resulting in increased protein expression. This product is ideal for applications such as CRISPR-based genome editing, immunotherapeutics, and recombinase studies.

CAT: BRP-02562

Concentration: 1.0 mg/mL

Description: CleanCap Cas9 mRNA is a specialized product designed to express the CRISPR-associated protein Cas9, a key component of the CRISPR genome editing system. This mRNA is capped using CleanCap technology, which produces a base-modified Cap-1 structure with superior in vivo activity compared to traditional Cap-0 mRNA. The mRNA is polyadenylated and may be modified with nucleotides like N1-methylpseudouridine or 5-methoxyuridine to enhance translational efficiency and reduce immunogenicity. CleanCap Cas9 mRNA is ideal for applications such as CRISPR-based genome editing, immunotherapeutics, and recombinase studies, providing researchers with a powerful tool for precise genetic modifications.

CAT: BRP-02563

Concentration: 1.0 mg/mL

Description: CleanCap OVA mRNA is a specialized product designed to express the ovalbumin (OVA) protein, which is commonly used as a model antigen in immunology and vaccine research. This mRNA is capped using CleanCap technology, which produces a base-modified Cap-1 structure with superior in vivo activity compared to traditional Cap-0 mRNA. The mRNA may also be modified with nucleotides like N1-methylpseudouridine (N1MePsU) or 5-methoxyuridine (5moU) to enhance translational efficiency and reduce immunogenicity. These modifications result in increased protein expression and improved mRNA stability, making it ideal for applications such as studying immune responses, vaccine development, and optimization of mRNA delivery protocols.

CAT: BRP-02564

Concentration: 1.0 mg/mL

Description: CleanCap OVA mRNA (5moU) is a specialized mRNA product encoding ovalbumin (OVA), a model antigen widely used in immunology and vaccine research. This mRNA features a CleanCap structure, which enhances in vivo activity compared to traditional Cap-0 mRNA. The mRNA is also modified with 5-methoxyuridine (5moU), a chemical modification that increases mRNA stability and reduces immunogenicity. These modifications result in improved protein expression and mRNA longevity, making it ideal for applications such as studying immune responses and developing mRNA-based vaccines.

CAT: BRP-02565

Concentration: 1.0 mg/mL

Description: CleanCap M6 EPO mRNA (N1MePsU) is a modified messenger RNA that encodes human erythropoietin (hEPO), a hormone essential for regulating red blood cell production and involved in wound healing and neural injury response. This formulation incorporates N1-methylpseudouridine (N1MePsU), a nucleotide modification that enhances mRNA stability and translational efficiency while reducing immunogenicity. The mRNA features a Cap-1 structure and a poly(A) tail, which further improve its stability and expression in mammalian systems. This modified mRNA is designed to provide robust expression of erythropoietin, making it suitable for applications in research and therapeutic development, particularly in conditions where enhanced red blood cell production or tissue repair is desired.

CAT: BRP-02566

Concentration: 1.0 mg/mL

Description: CleanCap EGFP mRNA (5-moUTP) is a chemically modified messenger RNA designed to express enhanced green fluorescent protein (EGFP), a widely used reporter gene. This mRNA incorporates 5-methoxyuridine (5-moUTP) to enhance stability and reduce immunogenicity. It features a Cap-1 structure and a poly(A) tail, further improving its stability and translation efficiency. This formulation is suitable for applications in research and therapeutic development, including studies on mRNA delivery, protein expression, and vaccine development.CleanCap EGFP mRNA (5-moUTP) provides robust expression of EGFP, making it an ideal tool for monitoring gene expression and protein localization in both in vitro and in vivo studies.

CAT: BRP-02567

Concentration: 1.0 mg/mL

Description: CleanCap Beta-galactosidase (β-gal) mRNA encodes the enzyme beta-galactosidase, a widely used reporter gene that catalyzes the hydrolysis of β-galactosides, such as lactose, into galactose and glucose. This enzyme is often used as a marker in genetic and molecular biology studies due to its ease of detection through colorimetric assays. The β-gal mRNA can be modified to enhance stability and reduce immunogenicity, making it suitable for applications such as evaluating gene expression, studying promoter activity, and developing mRNA vaccines. With features like a Cap-1 structure to improve translation efficiency, CleanCap β-gal mRNA serves as an essential tool in both research and therapeutic development, providing a reliable means to study cellular processes and develop new treatments.

CAT: BRP-02568

Concentration: 1.0 mg/mL

Description: CleanCap Beta-galactosidase (β-gal) mRNA (5-methoxyuridine, 5moU) is a modified messenger RNA designed to express the enzyme β-galactosidase, which is commonly used as a reporter gene to monitor gene expression and cellular processes. This mRNA incorporates 5-methoxyuridine (5moU) to enhance stability and reduce immunogenicity. The 5moU modification has been shown to increase protein expression while minimizing immune activation. The mRNA is typically capped with a Cap-1 structure and contains optimized 5' and 3' untranslated regions (UTRs) to further improve translation efficiency. This formulation is suitable for various applications, including gene expression studies, transfection efficiency assessments, and vaccine development. The β-gal enzyme itself catalyzes the hydrolysis of β-galactosides into monosaccharides and can be detected using substrates like X-gal, which turns blue upon cleavage, making it a convenient marker for visualizing gene expression.

CAT: BRP-02569

Concentration: 1.0 mg/mL

Description: CleanCap Renilla Luc mRNA (5-moU) is a modified messenger RNA designed to express Renilla luciferase, a bioluminescent reporter protein derived from the sea pansy (Renilla reniformis). This mRNA incorporates 5-methoxyuridine (5-moU) to enhance stability, reduce immune activation, and extend the duration of protein expression. It features a Cap-1 structure and a poly(A) tail to further improve translation efficiency and mRNA stability. CleanCap Renilla Luc mRNA (5-moU) is suitable for various applications, including gene expression studies, in vivo imaging, and assays to assess mRNA delivery and translation efficiency. Its bioluminescent properties make it an ideal tool for monitoring gene expression and cellular processes in real-time.

CAT: BRP-02570

Concentration: 1.0 mg/mL

Description: CleanCap Cre mRNA (5-moU) is a modified messenger RNA designed to express Cre recombinase, a powerful enzyme used for site-specific DNA recombination. This mRNA incorporates 5-methoxyuridine (5-moU) to enhance stability and reduce immunogenicity, making it suitable for applications in gene editing and conditional gene expression studies. It features a Cap-1 structure and a poly(A) tail to further improve translation efficiency and mRNA stability. CleanCap Cre mRNA (5-moU) is ideal for applications such as gene editing, conditional gene knockout, and in vivo studies, where long-term expression of Cre recombinase is required.

CAT: BRP-02571

Concentration: 1.0 mg/mL

Description: CleanCap Cas9 Nickase mRNA (5-moU) is a modified messenger RNA designed to express Cas9 Nickase, a variant of the CRISPR-Cas9 protein that introduces single-strand breaks (nicks) in DNA instead of double-strand breaks. This modification significantly reduces off-target effects, making it a powerful tool for precise genome editing. The mRNA incorporates 5-methoxyuridine (5-moU) to enhance stability and reduce immunogenicity, while featuring a Cap-1 structure and a poly(A) tail to further improve translation efficiency. CleanCap Cas9 Nickase mRNA (5-moU) is ideal for applications such as gene editing, base editing, and multiplex genome editing, where high specificity and reduced off-target effects are crucial.

CAT: BRP-02572

Concentration: 1.0 mg/mL

Description: CleanCap Cas9 mRNA (5-moU) is a modified messenger RNA designed to express the Cas9 protein, a key component of the CRISPR-Cas9 genome editing system. This mRNA is modified with 5-methoxyuridine (5-moU), which enhances its stability, reduces immunogenicity, and improves translation efficiency. The mRNA features a Cap-1 structure and a poly(A) tail, further optimizing its functionality in mammalian systems. It also includes nuclear localization signals (NLS) to increase the efficiency of DNA cleavage by directing the Cas9 protein to the cell nucleus. This product is ideal for CRISPR-based genome editing applications, offering a safer and more efficient alternative for precise genetic modifications.

CAT: BRP-02573

Concentration: 1.0 mg/mL

Description: CleanCap EPO mRNA (5-moU) is a modified messenger RNA designed to encode human erythropoietin (EPO), a hormone that controls red blood cell production and plays a role in wound healing and neural injury response. This mRNA is modified with 5-methoxyuridine (5-moU) to enhance stability, reduce immunogenicity, and improve translation efficiency. It features a Cap-1 structure, which is known for its superior in vivo activity compared to Cap-0 mRNA produced by traditional methods. The mRNA is also polyadenylated and optimized for mammalian systems, mimicking a fully processed mature mRNA. This formulation is suitable for applications such as gene replacement therapies, where enhanced protein expression and reduced immune activation are desired.

CAT: BRP-02574

Concentration: 1.0 mg/mL

Description: ARCA EGFP mRNA is a messenger RNA designed to express enhanced green fluorescent protein (EGFP), which is commonly used as a direct-detection reporter gene in mammalian cells. This mRNA is modified with ARCA (Anti-Reverse Cap Analog) to form a Cap 0 structure, which enhances mRNA stability and translation efficiency. It also features a poly(A) tail to further improve stability and translation initiation. ARCA EGFP mRNA is ideal for studying transfection and expression in mammalian cells through various fluorescence-based assays. It can be used as a control to monitor mRNA delivery, translation efficiency, and cellular localization.

CAT: BRP-02575

Purity: ≥95% (Agarose Gel Electrophoresis)

Appearance: Colorless liquid

Concentration: 1.0 mg/mL

Description: ARCA EGFP mRNA (5-moUTP) is a modified mRNA designed to express enhanced green fluorescent protein (EGFP) and serves as a direct-detection reporter mRNA. This product is ARCA-capped, poly(A)-tailed, and incorporates 5-methoxyuridine triphosphate (5-moUTP) to enhance stability, reduce immune activation, and improve translation efficiency. The ARCA (Anti-Reverse Cap Analog) cap structure ensures high translation efficiency by allowing the mRNA to be translated twice as efficiently as those initiated with traditional mCAP. The 5-moUTP modification suppresses RNA-mediated innate immune activation, while the poly(A) tail further stabilizes the mRNA and enhances translation initiation. It is suitable for studying transfection and expression in mammalian cells through various fluorescence-based assays, making it an ideal control for experiments requiring precise monitoring of mRNA delivery and protein expression.

CAT: BRP-02576

Purity: ≥95% (Agarose Gel Electrophoresis)

Appearance: Colorless liquid

Concentration: 1.0 mg/mL

Description: Firefly Luciferase mRNA (ARCA, 5mCTP, ψUTP) is a modified messenger RNA designed to express Firefly Luciferase, a bioluminescent reporter protein used for gene expression analysis and live-cell imaging. This mRNA incorporates several modifications to enhance its performance, ARCA capping ensures high translation efficiency, while 5-methylcytidine triphosphate (5mCTP) and pseudouridine triphosphate (ψUTP) modifications help inhibit RNA-mediated innate immune activation, increase mRNA stability, and improve expression efficiency. The mRNA also features a poly(A) tail to further enhance stability and translation initiation. It is suitable for applications such as gene expression studies, cell viability assays, and in vivo imaging, where stable and efficient protein expression is required.

CAT: BRP-02577

Purity: ≥95% (Agarose Gel Electrophoresis)

Appearance: Colorless liquid

Concentration: 1.0 mg/mL

Description: SpCas9 mRNA (ARCA, 5mCTP, ψUTP) is a modified mRNA designed to express the Streptococcus pyogenes Cas9 protein, a key component of the CRISPR-Cas9 genome editing system. This mRNA is optimized for high translation efficiency and reduced immune activation, incorporating ARCA (Anti-Reverse Cap Analog) capping, 5-methylcytidine triphosphate (5mCTP), and pseudouridine triphosphate (ψUTP) modifications. The ARCA cap enhances translation efficacy, while 5mCTP and ψUTP improve mRNA stability and reduce host cell immune responses. Additionally, the mRNA features a poly(A) tail to further stabilize the molecule and enhance translation initiation. It is suitable for applications such as genome editing, where precise DNA targeting and cleavage are required.

CAT: BRP-02578

Purity: ≥95% (Agarose Gel Electrophoresis)

Appearance: Colorless liquid

Concentration: 1.0 mg/mL

Description: ARCA Cy3 EGFP mRNA (5-moUTP) is a chemically modified mRNA designed to express enhanced green fluorescent protein (EGFP) and is labeled with the Cy3 fluorophore. This mRNA incorporates 5-methoxyuridine triphosphate (5-moUTP) to enhance stability and reduce immune activation, making it suitable for analyzing mRNA delivery and translation efficiency. The EGFP protein emits bright green fluorescence with an emission peak at 509 nm, while the Cy3 tag provides additional visualization capabilities with excitation and emission maxima at 550 nm and 570 nm, respectively. This product is capped with ARCA (Anti-Reverse Cap Analog) to ensure high translation efficiency and is polyadenylated to further stabilize the mRNA. It is ideal for determining mRNA delivery and localization in cells and can be used as a control in various fluorescence-based assays.

CAT: BRP-02579

Purity: ≥95% (Agarose Gel Electrophoresis)

Appearance: Pink liquid

Concentration: 1.0 mg/mL

Description: EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) is a modified messenger RNA designed to express Firefly Luciferase, a bioluminescent reporter protein. This mRNA incorporates 5-methoxyuridine triphosphate (5-moUTP) to enhance stability and reduce immune activation, and is capped with a Cap 1 structure using EZ Cap Reagent AG (3'OMe), which provides higher translation efficiency compared to Cap 0 structures. The mRNA also features a poly(A) tail to further stabilize the molecule and enhance translation initiation. The Cy5 label allows for easy detection and tracking of the mRNA in various applications. This formulation is ideal for gene expression studies, live-cell imaging, and high-throughput screening, where stable and efficient protein expression is required.

CAT: BRP-02580

Purity: ≥95% (Agarose Gel Electrophoresis)

Appearance: Blue liquid

Concentration: 1.0 mg/mL